Business Context and Reporting Period
This Form 8-K is a current report filed by Supernus Pharmaceuticals, Inc. on October 10, 2024. The filing serves to announce a scheduled corporate event rather than report periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the announcement of an upcoming data review event.
Guidance, Outlook, and Events
- Upcoming Event: The Company will host a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. Eastern Time.
- Subject Matter: The call will review data from the open-label Phase IIa study of SPN-820 for the treatment of treatment-resistant seizures.
- Access: A live webcast with presentation slides will be available at www.supernus.com and archived for 60 days.
- Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting they are subject to risks and uncertainties detailed in the Company's Form 10-K for the fiscal year ended December 31, 2023.
Investor Verification Checklist
- Verify the date and time of the October 17, 2024, webcast on the Company's investor relations website.
- Review the full press release (Exhibit 99.1) for additional context on the SPN-820 study design.
- Consult the most recent Form 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.
- Monitor the archived webcast post-event for the specific clinical data results regarding treatment-resistant seizures.